Influenza A vaccine intranasal - Altimmune

Drug Profile

Influenza A vaccine intranasal - Altimmune

Alternative Names: ADhVN1203/04.H5; Influenza A vaccine H5N1 - Altimmune; Influenza-virus-vaccine-Vaxin; NasoVAX; Seasonal-influenza-virus-vaccine-intranasal-Vaxin

Latest Information Update: 21 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vaxin
  • Developer Altimmune
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Influenza A virus H5N1 subtype

Most Recent Events

  • 20 Sep 2017 Phase-II clinical trials in Influenza-A virus H5N1 subtype (Prevention) in USA (Intranasal) (NCT03232567)
  • 20 Sep 2017 US FDA approves IND application for Influenza A vaccine intranasal in Influenza-A virus H5N1 subtype (Prevention)
  • 21 Aug 2017 Altimmune files an IND application with the US FDA in USA for Influenza A infection (Prevention)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top